Pfizer closes Baxter vaccine acquisition; Bavarian Nordic Ebola booster tests begin in the U.K.;

> Pfizer ($PFE) has closed its deal for Baxter's ($BAX) marketed vaccines portfolio. Release

> The first clinical trials of a Bavarian Nordic's Ebola vaccine booster, which may improve the effects of a vaccine from GlaxoSmithKline ($GSK), have begun at the U.K.'s Oxford University. Report

> The U.S. has approved GlaxoSmithKline's purchase of the bulk of Novartis' ($NVS) vaccine business. Report

> This year's flu vaccine is not as effective against the current strain of the influenza virus because the virus has mutated, the CDC says. Report

> Novavax ($NVAX) has won FDA fast-track designation for its RSV F vaccine. Release

And Finally... UC Berkeley students are working on a portable chip that healthcare providers can access without the Internet to view patient vaccination records, a tool that could make it easier to provide vaccines to children in developing countries. More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.